(Q48029219)

English

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.

scientific article published on 25 July 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. (English)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

chronic myeloid leukemia

0 references

1

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

Rashmi Kanagal-shamanna

7

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

Hagop Kantarjian

2

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

7 February 2018

20

object named as

Zeev Estrov

1 reference

Europe PubMed Central

7 February 2018

Srdan Verstovsek

15

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

7 February 2018

William G Wierda

14

object named as

William G Wierda

1 reference

Europe PubMed Central

7 February 2018

Gautam Borthakur

18

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

7 February 2018

19

object named as

Susan O'Brien

1 reference

Europe PubMed Central

7 February 2018

21

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

7 February 2018

12

object named as

Sherry Pierce

1 reference

Europe PubMed Central

7 February 2018

Guillermo Garcia-Manero

9

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

7 February 2018

Marina Konopleva

13

object named as

Marina Konopleva

1 reference

Europe PubMed Central

7 February 2018

Jorge Eduardo Cortes

22

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

7 February 2018

17

object named as

Tapan M Kadia

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

Elias J Jabbour

5

object named as

Elias J Jabbour

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

4

object named as

Koji Sasaki

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

16

object named as

Naval G Daver

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

8

object named as

Ghayas C Issa

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

Graciela M Nogueras-Gonzalez

6

object named as

Graciela Nogueras Gonzalez

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

11

object named as

Sara Dellasala

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

author name string

Ahmad Ghorab

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

Devendra Kc

10

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

language of work or name

0 references

publication date

25 July 2017

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

123

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

22

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

4391-4402

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

Management of CML-blast crisis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Prognostic Factors, Response to Treatment, and Survival in Patients With Chronic Myeloid Leukemia in Blast Phase: A Single-Institution Survey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Chronic myeloid leukemia: mechanisms of blastic transformation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5673547

29 September 2018

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30864

21 January 2018

Identifiers

10.1002/CNCR.30864

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

release_ll5iyzpsjfanzjjmlxvsyqsuse

0 references

0 references

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/28743165

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48029219&oldid=2117034764"